活動性類風濕性關節炎、乾癬性關節炎、僵直性脊椎炎、中度至重度乾癬 Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis

Tumor Necrosis Factor (TNF) Blocking Agent
Etanercept is a dimeric soluble form of the p75 tumor necrosis factor (TNF) receptor that specifically binds TNF alpha and TNF beta, rendering TNF biologically inactive. TNF is a naturally occurring cytokine involved in normal inflammatory and immune responses, and plays an important role in the inflammatory processes of rheumatoid arthritis, polyarticular juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

Absorption:
Bioavailability, subQ: 58%
Distribution:
Vd: 12 L
Elimination Half Life:
102 hours

Sepsis or at risk of sepsis syndrome (eg, immunocompromised, HIV positive)

B (FDA) B2 (AUS)

Infant risk cannot be ruled out.(MDX)

Common:
Dermatologic: Injection site reaction, skin rash
Gastrointestinal: Diarrhea
Respiratory: Upper respiratory infection
Headache <20220815>

Serious:
Cardiovascular: Congestive heart failure
Dermatologic: Erythema multiforme, Malignant melanoma, Necrotizing fasciitis, Primary cutaneous vasculitis, Skin cancer, Squamous cell carcinoma of skin, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Kaposi sarcoma <20220815>
Hematologic: Aplastic anemia (<0.01% ), Leukemia, Pancytopenia (<0.1% )
Hepatic: Reactivation of hepatitis B viral hepatitis (<0.01% )
Immunologic: Autoimmune hepatitis (<0.1% ), Cancer, Hepatosplenic T-cell lymphoma, Hypersensitivity reaction (<2% ), Malignant lymphoma
Neurologic: Demyelinating disease of central nervous system, Multiple sclerosis, Peripheral demyelinating neuropathy, Seizure, Transverse myelitis, acute
Ophthalmic: Optic neuritis
Respiratory: Tuberculosis (0.006% to 0.02% )
Other: Infectious disease.

Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis: SubQ

Once-weekly dosing: 50 mg once weekly; maximum dose (rheumatoid arthritis): 50 mg/week.

Twice-weekly dosing (off-label dose): 25 mg twice weekly
Plaque psoriasis:

Initial: 50 mg twice weekly for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully).

Maintenance dose: 50 mg once weekly (Some patients may require 50 mg twice weekly).

Juvenile idiopathic arthritis (>2 years):

Once-weekly dosing: (subQ) 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose

Twice-weekly dosing: (subQ) 0.4 mg/kg/dose twice weekly, given 72 to 96 hours apart; maximum dose: 25 mg/dose
Kawasaki disease; acute, adjunct therapy (>2 months):
Limited data available. (subQ) 0.8 mg/kg/dose for 3 doses; administer first dose immediately after completion of IVIG (day 0), then next 2 doses administered weekly
Plaque psoriasis (4-17 years):
(subQ) 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Refrigerate at 2 to 8 degrees C . Do not freeze or shake, and protect from light in the original container.